The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Zepbound Was Five Times Better at Reducing Breathing Disruptions Lilly said its final trial evaluated sleep apnea and weight ...
CNBC on MSN18d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
The Washington Post on MSN7d
FDA approves weight-loss drug Zepbound to treat sleep apneaThe Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback